Study to Evaluate the Safety and Efficacy of ASC40 Tablets in Combination With Bevacizumab in Subjects With rGBM

Phase 3 Active not recruiting 136 enrolled Ascletis Pharmaceuticals Co., Ltd.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a randomized, double-blind, controlled and multi-center Phase III clinical trial to evaluate the safety and efficacy of ASC40 tablets combined with bevacizumab in the treatment of adult patients with recurrent glioblastoma. After standard radiotherapy and chemotherapy (temozolomide), the subject first experienced clinical recurrence or progression.

Timeline

Start: 2022-01-21
Primary completion: 2025-06
Completion: 2025-06

Publications

Dembitz V, James SC, Gallipoli P. Targeting lipid metabolism in acute myeloid leukemia: biological insights and therapeutic opportunities. Leukemia. 2025 Aug;39(8):1814-1823. doi: 10.1038/s41375-025-02645-z. Epub 2025 May 22.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Denifanstat	Small molecule	100 mg/m2	Oral
Background	Bevacizumab	Monoclonal antibody	10 mg/kg	Intravenous

Study to Evaluate the Safety and Efficacy of ASC40 Tablets in Combination With Bevacizumab in Subjects With rGBM

Summary

Timeline

Publications

Drugs

Indications